Results 21 to 30 of about 2,666,341 (347)

Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial

Nature Communications, 2023
CDK4/6 inhibitors have shown a synergistic effect with anti-HER2 therapy in hormone receptor (HR)-positive and HER2-positive breast cancer (BC). In this phase 2 study (NCT04293276), we aim to evaluate a dual-oral regimen of CDK4/6 inhibitor dalpiciclib ...
Min Yan, Limin Niu, Huimin Lv, Mengwei Zhang, Jing Wang, Zhenzhen Liu, Xiuchun Chen, Zhenduo Lu, Chongjian Zhang, Huiai Zeng, Shengnan Zhao, Yajing Feng, Huihui Sun, Huajun Li   +13 more
doaj   +1 more source

Identification of signaling pathways in early mammary gland development by mouse genetics [PDF]

, 2004
The mammary gland develops as an appendage of the ectoderm. The prenatal stage of mammary development is hormone independent and is regulated by sequential and reciprocal signaling between the epithelium and the mesenchyme.
A Yang, AA Mailleux, AA Mill, C van Genderen, DL Chapman, GW Robinson, H van Bokhoven, J Foley, J Laurikkala, J Laurikkala, JJ Wysolmerski, JJ Wysolmerski, JM Veltmaat, JM Veltmaat, L Hennighausen, M Bamshad, ME Dunbar, OT Oftedal, T Andl, T Mustonen, TG Davenport   +20 more
core   +2 more sources

A family history of breast cancer will not predict female early onset breast cancer in a population-based setting [PDF]

, 2008
: BACKGROUND: An increased risk of breast cancer for relatives of breast cancer patients has been demonstrated in many studies, and having a relative diagnosed with breast cancer at an early age is an indication for breast cancer screening.
A Lucassen, A Ziogras, AE Guttmacher, Caroline Seynaeve, Catharina E Jacobi, Cecile TM Brekelmans, Cees J Cornelisse, Christi J van Asperen, CJ Van Asperen, CJ Van Asperen, Collaborative Group on Hormonal Factors in Breast Cancer, D Ford, D Steinmann, D Thompson, DA Berry, DM Eccles, DM Eccles, EB Claus, EB Claus, Elly MM Krol-Warmerdam, FE Harrell Jr, G Parmigiani, Geertruida H de Bock, H Eerola, Jan GM Klijn, Jannet Blom, Johannes C van Houwelingen, JP Klein, KF Hoskins, KL Nathanson, O Visser, PD Pharoah, Peter Devilee, R Gershoni-Baruch, Rob AEM Tollenaar, RW Blamey, The Breast Cancer Linkage Consortium   +36 more
core   +7 more sources

Overdiagnosis and overtreatment of breast cancer: Overdiagnosis in randomised controlled trials of breast cancer screening [PDF]

, 2005
Data from randomised controlled trials of mammographic screening can be used to determine the extent of any overdiagnosis, as soon as either a time equivalent to the lead-time has elapsed after the final screen, or the control arm has been offered ...
AB Miller, AB Miller, AB Miller, AB Miller, FE Alexander, FE Alexander, H Vainio, I Andersson, J Frisell, L Tabar, MF Yen, N Bjurstam, S Moss, S Moss, S Shapiro, S Shapiro, Sue Moss, SW Duffy, The Breast Screening Frequency Trial Group   +18 more
core   +3 more sources

Expert consensus on clinical applications of ovarian function suppression for Chinese women with early breast cancer (2024 edition) [PDF]

Zhongguo aizheng zazhi
In China, 60% of breast cancer patients were premenopausal women at the time of diagnosis. Compared with postmenopausal women, premenopausal women have strong ovarian function and secrete estrogen to promote breast cancer growth.
Committee of Breast Cancer Society, China Anti-Cancer Association
doaj   +1 more source

Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. [PDF]

, 2013
BackgroundVitamin D plays a role in cancer development and acts through the vitamin D receptor (VDR). Although African-Americans have the lowest levels of serum vitamin D, there is a dearth of information on VDR gene polymorphisms and breast cancer among
Chen, Zujian, Heber, David, Koeffler, H Phillip, Mishra, Dhruva K, Ong, May, Sarkissyan, Marianna, Sarkissyan, Suren, Shang, Xiying, Vadgama, Jaydutt V, Wu, Yanyuan   +9 more
core   +10 more sources

Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial

Nature Communications, 2023
Immunotherapy combined with chemotherapy has been demonstrated to be effective in early triple-negative breast cancer (TNBC). In this single-arm, phase II study with Simon’s two-stage design, we investigated the efficacy and safety of neoadjuvant ...
Chengzheng Wang, Zhenzhen Liu, Xiuchun Chen, Jianghua Qiao, Zhenduo Lu, Lianfang Li, Xianfu Sun, Chongjian Zhang, Xiayu Yue, Qingxin Xia, He Zhang, Min Yan   +11 more
doaj   +1 more source

Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. [PDF]

, 2014
Preventing breast cancer is an effective strategy for reducing breast cancer deaths. The purpose of chemoprevention (also termed preventive therapy) is to reduce cancer incidence by use of natural, synthetic, or biological agents.
Brown, Powel H, Litzenburger, Beate C
core   +1 more source

Exploring factors contributing to low uptake of the NHS Breast Cancer Screening Programme among Black African women in the UK [PDF]

, 2017
Breast cancer is the most common cancer among women in the United Kingdom (UK) accounting for about 15% of cancer deaths. The National Breast Cancer Screening Programme in the UK was introduced in 1988 to assist with early detection and better management
Ali, Nasreen, Bamidele, Olufikayo, Papadopoulos, Chris, Randhawa, Gurch   +3 more
core   +1 more source

Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy

BMC Cancer, 2023
Background Lipid metabolism disorders may be involved in the occurrence and development of breast cancer. This study aimed to investigate the serum lipid changes during neoadjuvant chemotherapy for breast cancer and the effect of dyslipidemia on the ...
Youzhao Ma, Minhao Lv, Peng Yuan, Xiuchun Chen, Zhenzhen Liu   +4 more
doaj   +1 more source